Abstract 【Objective】To investigate the expression and clinical significance of PSA and P504S in prostate cancer. 【Methods】 A total of 62 cases of prostate cancer and 32 cases of benign prostatic hyperplasia from May 2018 to May 2020 were selected for the study. The expression of P504S and PSA in prostate cancer tissues was detected by immunohistochemistry. The relationship of PSA and P504S expression with clinical pathological characteristics was analyzed. 【Results】The positive expression rates of P504S and PSA in prostate cancer were 93.55% (58/62) and 90.32% (56/62), which were significantly higher than their 0% (0/32) and 3.13% (1 /32), and the differences between the two groups were significant (all P<0.05). The positive expression of P504S and PSA in prostate cancer and benign prostatic hyperplasia was significantly different (P<0.05).The positive expression rate of P504S and PSA in prostate cancer increased with the increase of pathological grade, and the difference was statistically significant (P<0.05).In prostate cancer, the expression of P504S and PSA in high stage was significantly higher than that in low stage (P<0.05). The expression of PSA decreased in prostate cancer patients with higher Gleason score. While the expression of P504S increased with higher Gleason score. The difference was statistically significant (P<0.05). 【Conclusion】The expression levels of P504S and PSA can properly reflect the biological behavior of prostate cancer.
2021, Vol. 38 
